Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1984 May;49(5):567–570. doi: 10.1038/bjc.1984.90

Alpha 1-antitrypsin levels and phenotypes and hepatitis B serology in liver cancer.

L Sparos, Y Tountas, C Chapuis-Cellier, G Theodoropoulos, D Trichopoulos
PMCID: PMC1976722  PMID: 6326791

Abstract

Serum levels of alpha 1-antitrypsin (alpha 1 AT) were measured by radial immunodiffusion and phenotypes were determined by electrofocusing in acrylamide gel in 39 patients with hepatocellular carcinoma (HCC) positive for serum hepatitis B surface antigen (HBsAg), 41 patients with HCC negative for serum HBsAg, and 160 age- and sex-matched hospital controls. There was no difference between the control series and either of the two HCC groups with respect to alpha 1 AT phenotype pattern; also, there was no evidence of association between HCC and either the M2 allele or any of the alpha 1 AT deficiency phenotypes. However, HCC cases negative for HBsAg had significantly higher serum alpha 1 AT values (mean 665 +/- 26 mg 100 ml-1) than HCC cases positive for HBsAg (mean 571 +/- 23 mg 100 ml-1), who in turn, had significantly higher alpha 1 AT values than hospital controls (mean 434 +/- 13 mg 100 ml-1). These results indicate that in Greece, as in other high HCC incidence countries, genetically determined alpha 1 AT deficiency is not aetiologically important; the increase of serum alpha 1 AT is an important correlate of HCC with possible aetiologic significance and diagnostic potential and HBsAg-positive HCC and HBsAg-negative HCC are manifest differently as well as being aetiologically distinct.

Full text

PDF
567

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chapuis-Cellier C., Arnaud P. Preferential transmission of the Z deficient allele of alpha 1-antitrypsin. Science. 1979 Jul 27;205(4404):407–408. doi: 10.1126/science.313077. [DOI] [PubMed] [Google Scholar]
  2. Chio L. F., Oon C. J. Changes in serum alpha 1 antitrypsin, alpha1 acid glycoprotein and beta 2 glycoprotein I in patients with malignant hepatocellular carcinoma. Cancer. 1979 Feb;43(2):596–604. doi: 10.1002/1097-0142(197902)43:2<596::aid-cncr2820430229>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  3. Cox D. W. Genetic variation of alpha 1-antitrypsin. Am J Hum Genet. 1978 Nov;30(6):660–662. [PMC free article] [PubMed] [Google Scholar]
  4. Harpel P. C. Protease inhibitors--a precarious balance. N Engl J Med. 1983 Sep 22;309(12):725–726. doi: 10.1056/NEJM198309223091210. [DOI] [PubMed] [Google Scholar]
  5. Kelly J. K., Davies J. S., Jones A. W. Alpha-1-antitrypsin deficiency and hepatocellular carcinoma. J Clin Pathol. 1979 Apr;32(4):373–376. doi: 10.1136/jcp.32.4.373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kew M. C., Turnbull R., Prinsloo I. alpha1-Antitrypsin deficiency and hepatocellular cancer. Br J Cancer. 1978 Apr;37(4):635–638. doi: 10.1038/bjc.1978.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lam K. C., Yu M. C., Leung J. W., Henderson B. E. Hepatitis B virus and cigarette smoking: risk factors for hepatocellular carcinoma in Hong Kong. Cancer Res. 1982 Dec;42(12):5246–5248. [PubMed] [Google Scholar]
  8. Lellouch J., Claude J. R., Thevenin M. alpha 1-Antitrypsine et tabac, une étude de 1296 hommes sains. Clin Chim Acta. 1979 Jul 16;95(2):337–345. doi: 10.1016/0009-8981(79)90376-0. [DOI] [PubMed] [Google Scholar]
  9. Matsuzaki S., Iwamura K., Itakura M., Kamiguchi H., Katsunuma T. A clinical evaluation of serum alpha-1-antichymotrypsin levels in liver disease and cancers. Gastroenterol Jpn. 1981 Dec;16(6):582–591. doi: 10.1007/BF02813793. [DOI] [PubMed] [Google Scholar]
  10. Morse J. O. alpha1-antitrypsin deficiency (first of two parts). N Engl J Med. 1978 Nov 9;299(19):1045–1048. doi: 10.1056/NEJM197811092991905. [DOI] [PubMed] [Google Scholar]
  11. Palmer P. E., Ucci A. A., Wolfe H. J. Expression of protein markers in malignant hepatoma: evidence for genetic and epigenetic mechanisms. Cancer. 1980 Mar 15;45(6):1424–1431. doi: 10.1002/1097-0142(19800315)45:6<1424::aid-cncr2820450621>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  12. Sharp H. L. The current status of alpha-1-antityrpsin, a protease inhibitor, in gastrointestinal disease. Gastroenterology. 1976 Apr;70(4):611–621. [PubMed] [Google Scholar]
  13. Sizaret P., Clerc M., Estève J., Frants R. R., Pillot J. M2 alpha-1-antitrypsin phenotype and primary liver cancer. Br J Cancer. 1981 Feb;43(2):226–228. doi: 10.1038/bjc.1981.32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Spech H. J., Liehr H. Alpha 1-Antitrypsinmangel und Leber. Z Gastroenterol. 1982 Jul;20(7):393–404. [PubMed] [Google Scholar]
  15. Theodoropoulos G., Fertakis A., Archimandritis A., Kapordelis C., Angelopoulos B. Alpha 1-antitrypsin phenotypes in cirrhosis and hepatoma. Acta Hepatogastroenterol (Stuttg) 1976 Apr;23(2):114–117. [PubMed] [Google Scholar]
  16. Trichopoulos D., Kremastinou J., Tzonou A. Does hepatitis B virus cause hepatocellular carcinoma? IARC Sci Publ. 1982;(39):317–332. [PubMed] [Google Scholar]
  17. Trichopoulos D., MacMahon B., Sparros L., Merikas G. Smoking and hepatitis B-negative primary hepatocellular carcinoma. J Natl Cancer Inst. 1980 Jul;65(1):111–114. [PubMed] [Google Scholar]
  18. Trichopoulos D., Tabor E., Gerety R. J., Xirouchaki E., Sparros L., Munoz N., Linsell C. A. Hepatitis B and primary hepatocellular carcinoma in a European population. Lancet. 1978 Dec 9;2(8102):1217–1219. doi: 10.1016/s0140-6736(78)92097-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES